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Abstract
Animal experiments have served to improve our knowledge on diseases and treatment approaches since ancient times. Today, 
animal experiments are widely used in medical, biomedical and veterinary research, and are essential means of drug devel-
opment and preclinical testing, including toxicology and safety studies. Recently, great efforts have been made to replace 
animal experiments with in vitro organoid culture methods and in silico predictions, in agreement with the 3R strategy to 
“reduce, refine and replace” animals in experimental testing, as outlined by the European Commission. Here we present a 
mini-review on the development of animal testing, as well as on alternative in vitro and in silico methods, that may at least 
partly replace animal experiments in the near future.
Keywords Animal experiments · Drug development · Gene modifications · Transgenesis · Phenotype analysis · 3D 
organoid culture · In silico prediction
Introduction
Animal experiments date back to ancient times. At the very 
beginning experiments carried out on animals were driven 
by curiosity to get to know the living body, later followed 
by the demand to better recognize various pathologies and 
improve our knowledge on diseases. Today, animal experi-
ments are widely used in medical, biomedical, veterinary 
research and drug development, including toxicology and 
safety studies. However, the number of experimental animals 
used in a series of research cannot be extended limitless, 
and recently, great efforts have been made to replace animal 
experiments with in vitro organoid culture methods and in 
silico predictions. Here, we give an overview of the past 
and present of animal experiments, and discuss alternative 
strategies that may replace them in the future.
The past
Greek scientists such as Aristotle or Erasistratus are known 
to have executed animal experiments as early as in the sec-
ond century BC. Galenus, the famous Greek-Roman physi-
cian, regularly executed experiments on animals, including 
autopsy to improve his anatomical, physiological and patho-
logical knowledge (Hajar 2011).
However, the greatest value of animal testing is related to 
drug development. Two well-known examples clearly dem-
onstrate why it is necessary to test drugs on animals before 
human trials are started. In 1937, an American company 
launched a product called “Elixir Sulfanilamide,” containing 
sulfanilamide dissolved in diethylene glycol (DEG) and fla-
vored with raspberry. It was marketed without having been 
tested on animals and was blamed for hundreds of deaths 
and huge scandals (Hajar 2011). After the incident, under 
pressure from the public, the predecessor organization of 
the US Food and Drug Administration (FDA) was estab-
lished in the USA, and it ordered that all drug candidates 
should be tested for toxicity on animals before being placed 
on the market. Europe also had its own lesson after tha-
lidomide  (Contergan®) entered the market in 1957. It was 
recommended as a sedative and analgesic for the treatment 
of insomnia, fatigue and abdominal pain, as well as for 
the treatment of pregnancy-induced nausea and vomiting. 
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Consequently, from 1959 until its withdrawal about 10–20 
thousands of “Contergan babies” were born with limb 
abnormalities (hands and/or feet) in 46 countries world-
wide, except for the USA where the drug was not approved. 
Contergan was withdrawn from the market in 1961 (West-
ern Germany) and 1962 (all over the world) (Hajar 2011). 
These fatal drug experiences highlighted the necessity of 
well-designed animal testing.
The present
Today, animal experiments are widely utilized in medical 
and veterinary research and drug development, in fundamen-
tal biomedical research, and in preclinical toxicological and 
safety studies (Fig. 1). Animal models are suitable to thor-
oughly study the pathomechanisms of diseases, utilizing var-
ious in vivo tests and imaging techniques. During this pro-
cess affected organs and tissues can also be isolated at any 
stage in the development of pathology and can be subjected 
to in-depth studies using histological, immunohistochemi-
cal, electrophysiological and molecular biological methods, 
as well as imaging techniques (MRI, MEMRI, PET). Not 
merely does it improve our knowledge on diseases, but also 
facilitates an earlier and more reliable diagnosis. Medical 
students still acquire the basic knowledge and practice on 
small animals (dogs, rabbits) in many fields of medicine 
(e.g., cardio and vascular surgeries).
Various animal species are used for animal experiments, 
such as nematodes (C. elegans), flies (D. melanogaster), 
fishes (Zebra danio), frogs, birds, rabbits, dogs and mon-
keys; however, in drug development rats (15%) and mice 
(68%) are the most common species. In the last century, rats 
were widely used in drug research; thus, classical behavioral 
and physiological studies were developed for rats. To date, 
the entire rat genome has been sequenced (Gibbs et al. 2004) 
and transgenic rats have been generated (Bäck et al. 2019). 
From the end of the twentieth century, however, the use of 
mice exceeded that of rats in drug development. The wide-
spread use of mice for animal testing is justified by numer-
ous reasons: (a) their relatively inexpensive breeding, (b) 
fast reproduction (20-day-long gestation), (c) large number 
of offsprings (8–12), (d) early maturity (4–6 weeks), (e) 
well-characterized genome (the entire genome sequence is 
known) and (f) the fact that 99% of mouse genes have human 
homology. Well-developed genetic and molecular biological 
techniques (e.g., transgenesis, gene editing) are available for 
the experimental genomic manipulations of mice.
The pathomechanism of infective diseases is also mod-
eled by the artificial introduction of the pathogenic micro-
organisms (fungi, viruses, mycoplasmas, bacteria) into 
experimental animals. In other cases, chemical exposure 
is employed to model the pathologies characteristic for 
the particular disease studied. A good example for this is 
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) 
exposure, which selectively damages dopaminergic neurons, 
thereby making it possible to model Parkinson’s disease. 
As another possible methodology, pathological alterations 
can be induced via surgical approaches (e.g., artery/vein 
ligations) in order to model and study various pathologies 
(e.g., to study ischemic lesions, brain hypoxia, etc.). The 
animal models of human cancers are generated by graft 




Genetic diseases can be studied via the laboratory evolution 
of gene mutations in living organisms. Mutations also occur 
spontaneously in the nature, but their occurrence is quite 
rare (frequency: 5–10 × 10−6 per gene locus) (O’Brien and 
Frankel 2004). Point mutations can be randomly induced in 
the genome by chemical compounds such as base analogues 
(5-bromouracil, 2-aminopurine), acridine, alkylating agents, 
such as sulfur mustard, nitrogen mustard, ethyl-methanesul-
fonate (EMS), deaminating agents, hydroxylamine or free 
radicals. Initially, N-ethyl-N-nitrosourea (ENS) was used in 
male mice to mutate the germ cells in vivo and is now also 
used for the in vitro mutation of embryonic stem cells (ES 
cells). The resultant mutant ES cell lines allow for the gen-
eration of mutant mice, offering the opportunity to attempt 
to localize the site of mutation in an individual animal that 
shows a characteristic phenotype (O’Brien and Frankel 
2004). Another method of random mutagenesis is based on 
Fig. 1  Distribution of animal experiments (based on The Economist 
article published on August 31, 2007)
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X-ray irradiation of gametes, which is primarily used for 
genetic testing in D. melanogaster.
Insertional mutagenesis
Insertional mutagenesis is another means to induce random 
mutations. In this case, recombinant viral vectors (adenovi-
rus, retrovirus, lentivirus) or transposons are inserted into 
the genome. Significant progress has been made in mam-
malian gene transfer when the first DNA transposons were 
described at the end of twentieth century (Ivics et al. 1996). 
Using the transposase enzyme the transposons in the genome 
can be “jumped and pasted” optionally, so that virtually infi-
nite number of mutations can be generated. Although most 
of the known transposons have been isolated from fishes 
(Sleeping Beauty, Tol2, Passport), cabbage caterpillars (Pig-
gyBac) and frogs (Frog Prince), all of them work in mam-
malian cells without exception. On this field pioneer work 
has been done by the Hungarian scientists Z. Ivics and his 
coworker, Z. Izsvák (Ivics et al. 1996; Ivics et al. 1997). 
The newest type of transposons (PiggyBac, PiggyBat) will 
no longer leave “fingerprints” once they are skipped (i.e., 
certain sequences like C(A/T)GTA will not remain in their 
pre-insertion sites), so no mutations will emerge in their 
original environment (Skipper et al. 2013).
Creating transgenic animals
Definitely it was a major breakthrough when scientists were 
first able to artificially change the genome of living organ-
isms using cloned genes to create genetically modified ani-
mals. The first milestone in this respect was the generation 
of transgenic mice, later followed by the establishment of 
knock-out technique for targeted gene deletion. Today, it is 
even possible to perform subtle genetic manipulations, such 
as induced/tissue-specific gene targeting, or gene silencing 
with siRNA or miRNA molecules.
The introduction of various gene-transfer methods was 
a major step forward in the development of relevant animal 
models, in particular those that harbor not only somatic but 
also heritable genomic mutations. This includes the meth-
odology of viral (adenoviral and retroviral mediated) gene 
transfers into the reproductive organ, as well as the intro-
duction of sperm-mediated gene mutations through artificial 
insemination. However, the most prevalent technique is the 
pronuclear microinjection of ova with various recombinant 
DNA constructs and targeted gene knock-out (KO).
Pronuclear microinjection of egg cells with DNA 
constructs
The heritable genetic modification of the mouse genome was 
first reported in the early 1980s, based on the microinjection 
of purified recombinant DNA into the pronucleus of ferti-
lized mouse ova (Gordon et al. 1980; Harbers et al. 1981; 
Constantini and Lacy 1981). The technique spread rapidly 
and by the turn of the century thousands of transgenic mouse 
models were created worldwide using this technique. In 
Hungary, József Zákány introduced this technique in 1988 
after returning home from Columbia University, New York, 
and taught several young researchers who are still engaged 
in transgenesis-based research in Szeged, Gödöllő and Buda-
pest. The essence of this method includes isolating ferti-
lized oocytes from superovulated female mice, followed by 
the injection of the purified DNA construct into the male 
pronucleus of the ova. After a short recovery period the 
microinjected oocytes are reimplanted into the oviduct of 
foster mothers. The inserted transgene can be detected in 
the newborns by southern hybridization and/or polymer-
ase chain reaction (PCR). About 15–20% of the newborns 
are transgenic. Using this method even large DNA frag-
ments (75–100 kb) cloned into an appropriate vector (e.g., 
P1-phagemid) can be inserted into the mouse genome (Cal-
low et al. 1994).
Targeted gene editing
Classical gene knock‑out technology
The elements of the gene targeting technique have been 
developed independently by several laboratories. In the 
laboratory of Capecchi and Smithies researchers studied 
gene exchanges occurring via homologous recombination 
in mammalian cells (Folger et al. 1984; Kucherlapati et al. 
1984). Martin Evans and coworkers isolated and success-
fully maintained mouse embryonic stem (ES) cells in vitro 
(Evans and Kaufman 1981). When injected into blastocysts 
these cultured stem cells can differentiate into any bodily cell 
lines (ectoderm, mesoderm, endoderm) including the genital 
organs. The methodology of blastocyst injection was estab-
lished earlier, in 1968 (Gardner 1968). Capecchi, Smithies 
and Evans were awarded the Nobel Prize in Physiology and 
Medicine in 2007 for their breakthrough discoveries in the 
field of genetic modifications that can be performed in mice 
using embryonic stem cells.
The technique is quite complex and has many potential 
errors. As the first step a targeting vector should be cre-
ated, which is supposed to replace the homologous DNA 
sequences in the host cell. This is followed by the intro-
duction of the targeting vector into pluripotent ES cells, 
mainly via electroporation, where gene sequences exchange 
between the targeting vector and the endogenous gene via 
homologous recombination. Next, mutant ES cells should 
be selected using the appropriate positive selection marker 
(e.g., neo gene) and enriched with a negative selection 
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marker [e.g., thymidine kinase (TK) or diphtheria toxin 
(DT-A) genes] carried by the targeting vector. Selected 
clones are cloned and propagated. Then mutant ES cells are 
injected into mouse blastocysts which are re-implanted into 
the uterus of recipient female animals. The offsprings show 
various degrees of chimerism depending on the origin of 
their somatic cells. A high degree of chimerism indicates 
that most of the cells (including somatic and germ cells) 
originate from the mutant ES cell line. Next, male chime-
ras are crossed with wild-type black females, and when the 
gonads are adequately colonized with mutant ES cells, the 
mutation will be inherited to the progeny (germline trans-
mission). Most importantly, transformed stem cells retain 
their pluripotency during cultivation, transformation and 
selection, so that they can differentiate into cells of any type 
(ectoderm, endoderm and mesoderm) after re-introduction 
into blastocyst. Then newborns are tested for the inheritance 
of the desired mutation using southern hybridization and 
PCR. As a final step a transgenic line is established.
An alternative method of blastocyst injection is aggre-
gation of zona pellucida free mutant and wild-type blasto-
cysts in a Petri dish, in vitro. This method was developed 
by András Nagy and his coworker, Elen Gócza (Nagy et al. 
1990).
Novel methods of gene editing
Random gene modifications have necessarily been replaced 
by methods in which mutations can be introduced into a 
desired genetic locus, i.e., genetic manipulations can be 
targeted. Targeting genes at specific loci can be executed 
using for example zinc finger nuclease (ZFN), transcription 
activator-like effector nuclease (TALEN), clustered regularly 
interspaced short palindromic repeats (CRISPR-Cas9) and 
base editing. The various gene modification methods are 
summarized and compared in Table 1.
The zinc finger nuclease (ZFN) method
Zinc finger nucleases (ZFNs) are a class of engineered DNA-
binding proteins that facilitate targeted gene editing by creat-
ing double-strand breaks in DNA at user-specified locations. 
Each ZFN consists of two functional domains: a zinc finger 
protein (ZFP) domain that provides specific DNA binding 
and a DNA-cleavage domain. Zinc finger proteins (ZFPs) 
are the most abundant proteins in eukaryotes. They have 
multiple roles in DNA binding, RNA packaging, as well as 
in the regulation of gene transcription and apoptosis, protein 
folding and lipid binding (Laity et al. 2001). ZFPs consist of 
two antiparallel β-sheets and an α-helix and centrally bind 
a zinc ion through their  Cys2 and  His2 amino acids. Each 
zinc finger molecule consists of approximately 30 amino 
acid residues, of which amino acids at the − 1, + 3 and + 6 
positions can bind to three bases on the DNA strand assuring 
specific DNA binding. For example, the amino acid residues 
Arg (− 1), Glu (+ 3) and Thr (+ 6) specifically bind to the 
bases G, C and T, respectively (Fig. 2a) (Klug 2010). Next, 
the ZFP DNA-binding domain can be linked to Fok1 endo-
nuclease, which cleaves DNA at both strands when it forms 
dimers (Pavletich and Pabo 1991).
The TALEN method
The transcription activator-like effector nuclease (TALEN) 
technology uses artificial restriction enzymes generated by 
fusing a TAL effector DNA-binding domain to a DNA cleav-
age domain. Transcription activator like effector (TALE) is 
a virulence factor belonging to the type III secretion sys-
tem (injectosome) of Xanthomonas bacteria, and restriction 
enzymes are molecules with enzyme activity capable to 
cut DNA strands at any specific sequence. The main com-
ponent of the TAL effector molecule is a central domain 
consisting of 17.5 repeats. Each repeat domain contains 34 
Table 1  Comparison of gene modification methods
Gene modification method Purpose of application Location of gene manipulation References
Pronuclear microinjection Gene insertion Random Doench et al. (2016), Evans and 
Kaufman (1981), Folger et al. 
(1984)
Gene targeting Gene replacement gene insertion 
gene deletion
Targeted by homologous recombi-
nation
Gardner (1968), Gaudelli et al. 
(2017), Giandomenico et al. (2019), 
Gibbs et al. (2004), Gordon et al. 
(1980)
Zinc finger nucleases (ZFN) Gene deletion, insertion, replace-
ment
Targeted based on sequence-specific 
protein-DNA binding
Hajar (2011)
TALEN Gene deletion, insertion, replace-
ment
Targeted based on sequence-specific 
protein-DNA binding
Hartung (2010)
CRISPR-Cas9 Gene deletion, insertion, replace-
ment
Targeted based on sequence-specific 
crRNA-DNA binding
Ishino et al. (1987), Ivics et al. (1997)
Base editing Base replacement Targeted Klug (2010), Komor et al. (2016)
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amino acid residues, of which the 12th and 13th residues 
are called repeat variable diresidue (RVD) (Fig. 2b). These 
are highly variable and replaceable, while the 3′ end of the 
peptide domain is highly conservative. RVD is strongly cor-
related with specific nucleotide recognition. This relation-
ship between amino acid sequence and DNA recognition 
has allowed for the engineering of specific DNA-binding 
domains by selecting a combination of repeat segments con-
taining the appropriate RVDs. Supposing that an RVD site 
is composed of Asn-Gly, the peptide can bind to a T nucleo-
tide, while it binds to C when the RVD site is composed of 
His-Asp (Fig. 2b). This specific DNA binding domain is 
fused to Fok1 endonuclease, which upon dimerization cuts 
the recognized DNA sequences to make a double-strand 
break. The code of DNA-binding specificity of TAL Type 
III effectors was deciphered by Boch et al. (2009).
The CRISPR‑Cas9 method
The bacterial genome includes a specific gene cluster called 
CRISPR (clustered regularly interspaced short palindromic 
repeats) which, along with the Cas9 nuclease, represents 
an efficient bacterial defense system against invasive phage 
DNA (Ishino et al. 1987). Upon phage infection nucleases 
cut the foreign DNA, and the resultant DNA pieces are 
inserted and stored in the repeat region of the CRISPR locus. 
Upon a repeated phage infection, the bacterial CRISPR locus 
is activated, transcribed and is processed into smaller units 
of RNA (crRNA). Then crRNAs, harboring complementary 
sequences to the phage DNA, bind to the Cas9 endonuclease 
which cleaves the foreign DNA.
Groups led by F. Zhang and G. Church demonstrated for 
the first time that the CRISPR-Cas9 system works in mam-
malian cells as well (Cong et al. 2013). In the mammalian 
system a 20-mer long crRNA, which provides sequence 
specificity, is fused to an auxiliary trans-activating RNA 
(tracrRNA) to form a chimeric single-guide RNA (sgRNA). 
Next, they are linked to the CRISPR-associated protein 
(Cas9) that cuts target DNA at specific sites to generate 
double-strand breaks that induce DNA repair in the cells 
(Fig. 2c) (Cong et al. 2013). For a practical use, most com-
ponents of the CRISPR-Cas9 system have been cloned into 
a vector; thus, customers only need to insert their specific 
guide RNA sequences into this commercially available vec-
tor. RNA editing is also possible using a similar system, but 
in this case the Cas9 endonuclease is replaced by the Cas13 
nuclease which cuts single-stranded RNA (Mali et al. 2013).
Unfortunately, these engineered nuclease technologies 
(ZFN, TALEN and CRISPR/Cas9) have the disadvantage 
called “off-target” events that occur when complexes bind to 
and cleave non-specific sites causing undesirable mutations. 
The frequency of off-target effect can reach 50% in some 
cases, which is the major concern for therapeutic and clinical 
applications (Zhang et al. 2015). In the past few years sev-
eral laboratories have made serious efforts to overcome this 
problem and reduce the number of off-target events (Doench 
et al. 2016; Li et al. 2019).
These novel techniques of gene editing have success-
fully been using in several Hungarian laboratories, includ-
ing the Laboratories of G. Szabó and F. Erdélyi (Institute 
of Experimental Medicine (KOKI), Budapest), A. Dinnyés 
(Szent István University, Gödöllő), Z. Bősze, E.Gócza and 
L. Hiripi (National Agricultural Research and Innovation 
Centre, Gödöllő) to generate gene-modified animals.
Fig. 2  Schematic illustration of gene editing techniques. a Zinc-finger 
method (based on Klug 2010); b TALEN method (based on Boch 
et  al.  2009) c CRISPR-Cas9 method (based on Mali et  al.  2013). 
PAM (protospacer adjacent motif), tracrRNA (transactivating crRNA)
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Base editing
Base editing is one of the latest breakthroughs in gene tech-
nology and gene therapy. The spontaneous deamination of 
cytosine is a major source of C-G to T-A transitions, which 
account for about half of all known human pathogenic point 
mutations (Gaudelli et al. 2017). The methodology of base 
editing was introduced by Liu and coworkers (Komor et al. 
2016). Using base editing they have demonstrated that 
reversing a TA mutation into CG, and thus correcting this 
mutation, is feasible. In their system the guide RNA that 
provides sequence specificity is linked to a defective Cas9, 
which unzips the DNA, and makes a nick on the opposite 
strand (non-edited DNA strand) to trigger DNA repair. The 
defective Cas9 is linked to a base editing enzyme (i.e., aden-
osine deaminase) that turns A into inositol (I). During the 
process of DNA repair I is read as G on the edited strand, 
and C is inserted by DNA polymerase on the opposite strand 
during DNA replication (Komor et al. 2016). In some cases 
researchers also link a DNA glycosylase inhibitor to the base 
editing complex to prevent the repair of deamination. Using 
base editing A-T can be converted into G-C, and C-G can be 
converted into C-A in the mammalian genome, correcting 
the existing genetic point mutations.
Investigating the phenotype of genetically modified 
animals
In recent decades, several “factories” have been established 
to produce genetically modified mice. Hundreds of mutant 
mice have been produced by Lexicon Pharmaceuticals (The 
Woodlands, TX, USA) using gene targeting, by the Sanger 
Institute (England, Great Britain) using ethane–methane 
sulfonate (EMS) mutagenesis or by the Jackson Laborato-
ries (Bar Harbor, Maine, USA) using TALEN and CRISPR-
Cas9 gene-editing methods. Creating mutations in the mouse 
genome is relatively easy; however, determining the pheno-
typic changes induced by a certain mutation is an extremely 
difficult and complex task. Detailed histological, biochemi-
cal, genetic and molecular biological studies should be 
performed to ensure and validate that genetically modified 
animals undergo the phenotypic changes similar to those 
characteristics of the modeled disease. Therefore, studying 
the phenotype is a complex and multifaceted task, requiring 
expertize in immunological, electrophysiological, behavioral 
tests and imaging techniques, as well as in-depth and up-
to-date knowledge on brain, heart, kidney, liver, pancreas, 
spleen or gonad-specific functionalities. Therefore, several 
international consortia (e.g., EUMODIC, the European Con-
ditional Mouse Mutagenesis) have been established with a 
huge financial effort to analyze mutant phenotypes in details. 
The primary phenotype analysis, including tests based on an 
experimental panel, is carried out by four large European 
laboratories. Their results are public and accessible to any-
one via the EuroPhenome Web site (http://www.europ henom 
e.org/). In 2013, at the Helmholtz Center in Munich, a non-
profit company, Infrafrontier GmbH, was established with 
the support of five countries (Germany, France, Finland, the 
Czech Republic and Greece) to coordinate the work of Euro-
pean laboratories engaged in phenotype analyses of trans-
genic mouse models. The German Mouse Clinic (GMC) was 
among the first phenotyping facilities to establish a wide-
spread collaboration-based platform for phenotype char-
acterization of mouse lines (Fuchs et al. 2018). The GMC 
has advanced development pipelines and offer a large scale 
of standardized and comprehensive phenotypic analysis of 
mouse mutants for various disease areas, such as screens 
for cognitive, memory, sensory and motor deficits, screens 
for neurobehavioral assessment, glucose metabolism, kidney 
function, energy metabolism, immune functions, allergies 
and lung functions (Fuchs et al. 2018).
How relevant are animal models in characterizing 
human diseases?
Dozens of human diseases are studied in mouse models. 
For example, a natural mutation of mice, which results in a 
small-eyed phenotype, is an excellent model for the devel-
opment of human aniridia. Genetic research has revealed 
that a mutation in the PAX6 gene (haploinsufficiency of 
PAX6) is responsible for disease development in both mice 
and humans (Porteous and Dorin 1993). The first human 
disease modeled in mice was the Lesch–Nyhan syndrome, 
a progressive neurological disorder with a striking feature 
of self-mutilating behavior. Mutation of the hypoxanthine 
phosphoribosyl transferase (HPRT) gene involved in pro-
line metabolism is responsible for the development of the 
human disease. HPRT-deficient mice were produced by ES 
cell technology, and surprisingly, knock-out mice appeared 
to be unaffected, showing normal behavior (Hooper et al. 
1987; Kuehn et al. 1987). It was hypothesized that quantita-
tive differences in purine metabolism between human and 
mice may explain this finding. However, Wu and Melton 
revealed that mice rather use another enzyme, adenosine 
phosphoribosyltransferase (APRT) for their purine salvage. 
Indeed, administration of an APRT inhibitor induced per-
sistent self-harm behavior in HPRT-deficient mice (Wu and 
Melton 1993). Currently, many human diseases, such as 
Gaucher disease, cystic fibrosis, Waardenburg syndrome, 
Duchenne muscular dystrophy, sickle-cell anemia, athero-
sclerosis, Alzheimer’s disease, Parkinson’s disease or Li-
Fraumeni disease, have adequate mouse models. Although 
the full scale of pathological alterations may be different in 
mice compared to humans, currently mouse models are the 
best means of understanding diseases and developing novel 
therapies.
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There is no doubt, however, that great advances have been 
made in the development of in vitro methods recently. These 
include stem cell differentiation, metastasis tracking or arti-
ficial blood–brain barrier formation, but in many cases we 
are not yet able to study living processes without the whole 
body.
The future
The future of animal experiments and drug 
development in the twenty‑first century
A recent study carried out by two animal welfare groups 
found that the number of animal tests requested by the US 
Environmental Protection Agency (EPA) has increased dra-
matically in 2017 and involved about 75,000 rats, rabbits, 
and other vertebrates (Zainzinger 2018). Such a high use 
of experimental animals drew the attention of scientists, 
and great efforts are made to replace animal experiments 
with alternative methods. Tissue cultures, perfused organs, 
histological sections or cell infection models are promising 
in vitro alternatives. In animal testing the recommendations 
issued by the European Commission encourage adherence 
to the 3Rs strategy (replacement, reduction, refinement) out-
lined by Russell and Burch (1959). Specifically, replacement 
refers to the absolute and relative replacement of experimen-
tal animals either by inanimate systems (e.g., in vitro orga-
noids or computer programs) or by other species indicated 
to have a significantly lower potential for pain perception, 
such as some invertebrates. Reduction refers to the rational 
reduction of the number of experimental animals used and/
or the maximization of the amount of information obtained 
per animal. Refinement refers to the treatments applied in the 
experiments, comprising the efforts to alleviate or minimize 
the potential pain, suffering or distress for the experimental 
animals used, assuring enhanced animal welfare. Thus, the 
3Rs strategy aims to make animal experiments more accept-
able and humane (Russell and Burch 1959). Recently, the 
original 3Rs have been extended with the terms of Reuse, 
referring to using the same animals in a later experiment 
when it is possible, and Rehabilitation of the animals after 
their use.
3D in vitro organoid cultures
Animal disease models are constructed with a dual purpose. 
On the one hand, they offer a means to monitor the develop-
ment and the course of a disease by detailed histological, 
molecular biology and imaging studies. On the other hand, 
they are utilized to test the in vivo toxicity, efficacy and phar-
macokinetic characteristics of candidate drug molecules. 
However, toxicity testing requires the use of a large number 
of experimental animals, and thus it is an area where the 
principle of substitution can and should be followed in the 
future. Recently, great efforts have been made to develop 
human 3D tissue chip, organ-on-a-chip (Pitsalidis et al. 
2018), 3D transwell cultures, self-assembling organ cultures 
(Li et al. 2017) and air–liquid interface cerebral organoid 
(ALI-CO) cultures (Giandomenico et al. 2019) to replace 
experimental animals. Such 3D cultures modeling the lung, 
the liver, the heart, the intestines, the lymph nodes and the 
brain are already available (Proceedings of a Workshop, 
Chapter 5, 2018). The in vitro ALI-CO culture developed 
by Giandomenico et al. was maintained for 10–12 months 
and exhibited active neuronal networks and subcortical pro-
jecting tracts innervating mouse spinal cord explants. This 
organoid culture was even capable of eliciting coordinated 
muscle contractions when co-cultured with mouse spinal 
cord–muscle explants (Giandomenico et al. 2019). Further-
more, the development of in vitro human brain organoid 
models of the blood–brain barrier (BBB) offers the possibil-
ity to investigate the penetrability of various drugs through 
the BBB (Nakagawa et al. 2009, Kamal and Waldau 2019). 
Using photopolymerizable hydrogels Miller’s group has suc-
cessfully printed an artificial 3D “lung” to explore the oxy-
genation and flow of human red blood cells in a vascularized 
alveolar model (Grigoryan et al. 2019).
Recently, promising experiments have been reported 
using scaffold-free 3D cell lines or primary cells in a sphe-
roid suspension culture. Spheroid cultures can be easier to 
establish and simpler to work with compared to 3D-printed 
models that require a pre-designed scaffold (Tanabe 2019).
Molecularly refined personalized treatments may also 
be possible in the near future based on information gained 
from 3D organ cultures established from the patient’s own 
tissues. Noor et al. (2019) isolated omental tissue samples 
from patients, and the cells were reprogrammed to pluri-
potent stem cells and then differentiated into cardiomyo-
cytes and endothelial cells combined with hydrogels to form 
“bioinks”. The researchers then 3D printed a complete small 
heart, having the blood vessels and chambers. An alterna-
tive technique is to obtain inducible pluripotent stem cells 
(iPSCs) from the patient’s blood, which can be differentiated 
in chemically well-defined media in vitro to produce the 
patient’s own 3D organ culture (Burridge et al. 2016a, b).
In silico toxicology
To reduce the vast number of experimental animals required 
for toxicological and safety studies, a very important step 
forward is the emergence of the so-called twenty-first-cen-
tury toxicology which replaces in vivo animal testing by 
processing in vitro and in silico toxicological data (Hartung 
2010). The core of this novel methodology is to compare 
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the chemical structure and physiological activities (potential 
toxic effects) of compounds using various computer models 
(Raies and Bajic 2016; Kling 2019), (Fig. 3).
Hartung and his coworkers created a map of the known 
chemicals by comparing about 10 million structurally simi-
lar molecules (Kling 2019). In a detailed computational 
analysis 190,000 chemicals with known classification as 
toxic or non-toxic were compared to the respective predic-
tion, and the accuracy of the model to predict toxicity was 
found to be 87%. By comparison, when an animal experi-
ment was repeated using the same drug molecule, the same 
result occurred in only 81% of cases, indicating that novel 
computational approaches can outperform the reproducibil-
ity of animal tests (Kling 2019; Luechtefeld et al. 2018).
Conclusions for future biology
We can hypothesize that time is not far off when the cur-
rently essential animal experiments may be at least partly 
replaced by in vitro and in silico methodologies. By process-
ing hundreds of thousands of in vivo, in vitro and in silico 
data using mathematical models, such as quantitative struc-
ture–activity relationship (QSAR), read-across structure 
activity relationships (RASAR) and artificial intelligence 
(AI), we could be able to accurately predict the human tox-
icities and physiological effects of most chemicals. This is in 
agreement with the strategy to “reduce, refine and replace” 
animals in experimental testing, as outlined by the European 
Commission, as well as by the Environmental Protection 
Agency of the USA.
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